HSTO Histogen Inc.

Histogen, Inc. engages in the development of patented, innovative technologies that replace and regenerate tissues in the body for the aesthetic and therapeutic markets. Its technology is based on the discovery that growing fibroblast cells under simulated embryonic conditions induces them to become multipotent stem cells. The environment created by its proprietary process mimics the conditions within the womb very low oxygen and suspension. When cultured under these conditions, the induced multipotent stem cells generate biological materials that stimulate a patient's own stem cells to activate and regenerate tissue. This results in potential therapeutic benefits in multiple treatment settings, including skin care, orthopedic indications such as cartilage formation and spinal disc repair, wound healing and dermal fillers. The company was founded on July 13, 2005 by Steven J. Mento and is headquartered in San Diego, CA.

$1.04
As of 06/24/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/29/2013
Outstanding shares:  35,751,957
Average volume:  3,727,145
Market cap:   $39,327,153
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    43358Y103
ISIN:        US43358Y1038
Sedol:      BMC5BS1
Valuation   (See tab for details)
PE ratio:   -1.74
PB ratio:   1.63
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy